<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831272</url>
  </required_header>
  <id_info>
    <org_study_id>807991</org_study_id>
    <secondary_id>5R01AA017164-05</secondary_id>
    <nct_id>NCT00831272</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Response to Naltrexone For Alcohol Dependence</brief_title>
  <official_title>Pharmacogenetic Response to Naltrexone for Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Oslin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are to test for treatment outcome differences in alcohol dependent
      subjects randomly assigned to 12 weeks of treatment with NTX (50mg/day) or placebo among
      those with one or two copies of the Asp40 allele of the mu-opioid receptor compared to those
      homozygous for the Asn40 allele. Thus, the design of the study is a 2X2 cell double-blind
      randomization to NTX or placebo stratified by genotype. To meet these aims, 150 alcohol
      dependent outpatients with one or two copies of the Asp40 variant of the mu-opioid receptor
      and 190 subjects homozygous for the Asn40 variant will be recruited across the four
      participating sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the well established efficacy of naltrexone, there are significant variations in
      individual responses to naltrexone. A critical question remains: under what circumstances and
      for which patients will naltrexone (NTX) be most beneficial? Recent work at our center
      provides evidence that the mu-opioid receptor (OPRM1) gene polymorphism A118G (Asn40Asp)
      imparts a significant change in treatment response. We have shown that patients with 1-2
      copies of the Asp40 variant have significantly better treatment responses than patients with
      Asn40 variant (absence of heavy drinking -73.9% v/s 49% response). To further consolidate our
      knowledge, we wish to test the relationship between A118G polymorphism and the response to
      treatment with naltrexone. This work is focused on subjects of European or Asian descent as
      the A118G polymorphism occurs in less than 1% of those of African descent.

      The study consists of 12 weeks of outpatient treatment with 50mg/day of naltrexone or
      placebo. Up to 340 subjects will be recruited across four sites. The inclusion criteria
      include adult males and females of European or Asian descent with DSM-IV diagnosis of alcohol
      dependence and heavy drinking per TLFB criteria. Patients with major psychiatric disorders or
      on psychotropic medications, other substance dependence problems (except nicotine), severe
      cognitive impairment, active suicidal/homicidal thoughts and serious medical conditions
      (including liver disorders) will be excluded.

      The ultimate aim of this line of investigation is to further establish a genetic link between
      alcohol dependence and treatment by defining an endophenotype associated with treatment
      response.

      Based upon these very promising findings, the aim of this study is to examine prospectively
      the interaction between a functional polymorphism of the mu-opioid receptor (A+118G
      (Asn40Asp)) and response to treatment with naltrexone. A secondary aim of this study is to
      examine the role of the Asp40 allele in alternating the subjective effects from alcohol use
      in alcohol dependent individuals that have been demonstrated in human laboratory experiments.

      We hypothesize that naltrexone - but not placebo - will produce a greater clinical response
      during the 12 weeks of the trial in subjects with one or two copies of the Asp40 variant
      (&quot;Asp40 positives&quot;) than in subjects homozygous for the Asn40 allele. Response to naltrexone
      will be measured by a reduction in the number of heavy drinking days (as defined by &gt;5
      drinks/day for males; &gt;4 for females) during the 12 weeks of the trial.

      We also expect that there will be an interaction between medication and genotype such that,
      as compared to the groups on placebo or homozygous for Asn40, Asp40 positive subjects
      randomized to naltrexone will report less &quot;high&quot; from alcohol consumption (on the Biphasic
      Alcohol Effects Scale), and the lowest levels of alcohol craving over time (on the Penn
      Alcohol Craving Scale).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2009</start_date>
  <completion_date type="Actual">January 15, 2014</completion_date>
  <primary_completion_date type="Actual">December 20, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response to Naltrexone, as Measured by a Reduction in the Percent Days of Heavy Drinking Days (as Defined by &gt;5 Drinks/Day for Males; &gt;4 for Females) During the 12 Weeks of the Trial.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg/day of naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone</intervention_name>
    <description>50mg/day</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant is male or female, 18 years of age or older, and of European or Asian
             descent.

          2. Participant has a current DSM-IV diagnosis of alcohol dependence using the SCID/MINI.

          3. The participant has signed a witnessed informed consent form.

          4. Participant meets the following drinking criteria as measured by the Timeline Follow
             Back (TLFB): a. Drinks at least an average of 21 drinks/wk in the 60-day period prior
             to intake and b. Has 2 or more days of heavy drinking (defined as 5 or more drinks per
             day in males, 4 or more in females) in this same pre-treatment period.

          5. Participant has at least 48 hours of abstinence, as determined by subject report and
             breathalyzer measure immediately prior to randomization.

          6. Participant scores below 8 on the Clinical Inventory of Withdrawal from Alcohol (CIWA)
             prior to starting Naltrexone.

          7. Participant has adequate vision, hearing and ability to communicate to allow study
             participation.

          8. Participant is able to speak, print and understand English.

        Exclusion Criteria:

          1. Participant meets DSM-IV criteria for dependence on any substance other than alcohol
             or nicotine in the last 6 months.

          2. Participant has tested positive on the urine drug screen for opioids, benzodiazepines,
             or cocaine at the screening visit. Presence of THC is allowable.

          3. Participant has a current or lifetime DSM-IV diagnosis of bipolar affective disorder,
             schizophrenia, or any psychotic disorder.

          4. Participant has presence of unstable or serious medical illness such as a recent
             stroke, idiopathic seizure disorder, or cardiac disease.

          5. Participant has severe liver disease (SGPT (ALT) or SGOT (AST) of at least 3 times
             normal value at the time of randomization or an elevated Total Bilirubin level without
             evidence of Gilbert's Syndrome.

          6. Participant has taken any psychotropic medications (including disulfiram) regularly
             within the last seven days (14 for fluoxetine) prior to randomization or needs
             immediate treatment with a psychotropic medication (antidepressant, antipsychotic,
             benzodiazepine, or mood stabilizing medication). EXCEPTIONS: Zolpidem and ramelteon
             used sparingly if necessary for sleep; Oxazepam for alcohol detoxification; Seizure
             disorder medications.

          7. Participant is over the age of 64 and has evidence of severe cognitive impairment as
             evidenced by a Mini-mental status exam (MMSE) score &lt; 24.

          8. Participant meets DSM-IV criteria for current major depression (non-substance
             induced), PTSD, or panic disorder.

          9. Participant has suicidal or homicidal ideation necessitating inpatient
             hospitalization.

         10. Participant is a pre-menopausal female who is pregnant, nursing, or not using a
             reliable method of contraception.

         11. Participant is over age 64 and has evidence of severe cognitive impairment as
             evidenced by a Mini-mental status exam (MMSE) score less than 20.12. Participant is of
             African descent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Oslin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania/ Philadelphia VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. JAMA Psychiatry. 2015 May;72(5):430-7. doi: 10.1001/jamapsychiatry.2014.3053.</citation>
    <PMID>25760804</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <results_first_submitted>January 16, 2017</results_first_submitted>
  <results_first_submitted_qc>March 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2017</results_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>David Oslin</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A sample of participants was recruited through advertisements in local media, referrals from physicians, or self-referrals. Recruitment occurred between January 2009 and September 2013. Participants were recruited from 5 sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone Group ASP 40 Group</title>
          <description>50mg/day of naltrexone and ASP 40 carrier</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group ASP 40 Group</title>
          <description>Placebo group and ASP 40 carrier</description>
        </group>
        <group group_id="P3">
          <title>Naltrexone Group ASN 40 Group</title>
          <description>Naltrexone 50mg/day and ASN 40 carrier</description>
        </group>
        <group group_id="P4">
          <title>Placebo Group ASN 40 Group</title>
          <description>Placebo plus ASN 40 Carrier</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone Group ASP 40 Group</title>
          <description>50mg/day of naltrexone and ASP 40 carrier</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group ASP 40 Group</title>
          <description>Placebo group and ASP 40 carrier</description>
        </group>
        <group group_id="B3">
          <title>Naltrexone Group ASN 40 Group</title>
          <description>Naltrexone 50mg/day and ASN 40 carrier</description>
        </group>
        <group group_id="B4">
          <title>Placebo Group ASN 40 Group</title>
          <description>Placebo plus ASN 40 Carrier</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="66"/>
            <count group_id="B5" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" spread="13.4"/>
                    <measurement group_id="B2" value="46.9" spread="11.8"/>
                    <measurement group_id="B3" value="51.2" spread="13.0"/>
                    <measurement group_id="B4" value="48.2" spread="11.9"/>
                    <measurement group_id="B5" value="48.2" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% Days Heavy Drinking</title>
          <units>% days of heavy drinking</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="29.8"/>
                    <measurement group_id="B2" value="72.5" spread="27.8"/>
                    <measurement group_id="B3" value="67.5" spread="26.8"/>
                    <measurement group_id="B4" value="70.9" spread="28"/>
                    <measurement group_id="B5" value="69.9" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% Days Drinking</title>
          <units>% days of any drinking</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.9" spread="23.1"/>
                    <measurement group_id="B2" value="82.7" spread="20.9"/>
                    <measurement group_id="B3" value="82.8" spread="20.2"/>
                    <measurement group_id="B4" value="82.5" spread="19.8"/>
                    <measurement group_id="B5" value="81.9" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response to Naltrexone, as Measured by a Reduction in the Percent Days of Heavy Drinking Days (as Defined by &gt;5 Drinks/Day for Males; &gt;4 for Females) During the 12 Weeks of the Trial.</title>
        <time_frame>12 weeks</time_frame>
        <population>Repeated weekly measures of drinking outcomes were compared using generalized estimating equation models (GEE). The explanatory variables of primary interest comprised binary indicators for intervention group, genotype, and their interaction, a linear trend for time, and terms for interactions involving time and the group and genotype factors.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone Group ASP 40 Group</title>
            <description>50mg/day of naltrexone and ASP 40 carrier</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group ASP 40 Group</title>
            <description>Placebo group and ASP 40 carrier</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Group ASN 40 Group</title>
            <description>Naltrexone 50mg/day and ASN 40 carrier</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group ASN 40 Group</title>
            <description>Placebo plus ASN 40 Carrier</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response to Naltrexone, as Measured by a Reduction in the Percent Days of Heavy Drinking Days (as Defined by &gt;5 Drinks/Day for Males; &gt;4 for Females) During the 12 Weeks of the Trial.</title>
          <population>Repeated weekly measures of drinking outcomes were compared using generalized estimating equation models (GEE). The explanatory variables of primary interest comprised binary indicators for intervention group, genotype, and their interaction, a linear trend for time, and terms for interactions involving time and the group and genotype factors.</population>
          <units>percentage of heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="21.7"/>
                    <measurement group_id="O2" value="17.9" spread="21.8"/>
                    <measurement group_id="O3" value="14.5" spread="19.0"/>
                    <measurement group_id="O4" value="21.7" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Generalized Estimating Equation</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were ascertained weekly.</time_frame>
      <desc>AE's were only counted if reported at a level of moderate to severe by patient self report.</desc>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone Group ASP 40 Group</title>
          <description>50mg/day of naltrexone and ASP 40 carrier</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group ASP 40 Group</title>
          <description>Placebo group and ASP 40 carrier</description>
        </group>
        <group group_id="E3">
          <title>Naltrexone Group ASN 40 Group</title>
          <description>Naltrexone 50mg/day and ASN 40 carrier</description>
        </group>
        <group group_id="E4">
          <title>Placebo Group ASN 40 Group</title>
          <description>Placebo plus ASN 40 Carrier</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitlized</sub_title>
                <description>Diabetes</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>inpatient detoxification</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI complaints</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>worsening pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Change in libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>While the study did not achieve the intended sample size, it is highly unlikely that a larger sample would have resulted in the demonstration of the expected moderating effect of the Asp40 allele.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Oslin</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215 823 5894</phone>
      <email>oslin@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

